Lomustine

Generic Name: Lomustine

Brand Names: Ceenu, Gleostine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₆ClN_₃O_₂

CAS Number: 13010-47-4

Unique Ingredient Identifier: 7BRF0Z81KG

Background: An alkylating agent of value against both hematologic malignancies and solid tumors.

Indication: For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.

Associated Conditions: Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma

Associated Therapies: -

Clinical Trials

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Phase 1

Terminated

Conditions: Glioblastoma

Interventions: Drug: Dasatinib
Drug: Lomustine

First Posted Date: 2009-07-29

Last Posted Date: 2012-08-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT00948389

Locations: 🇨🇭
Local Institution, Lausanne, Switzerland

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Phase 3

Terminated

Conditions: Anaplastic Astrocytoma
Glioblastoma

Interventions: Drug: temozolomide
Drug: trabedersen
Drug: carmustine
Device: Drug delivery system for administration of AP 12009
Procedure: Placement of Drug Delivery System
Drug: lomustine

First Posted Date: 2008-09-29

Last Posted Date: 2014-11-14

Lead Sponsor: Isarna Therapeutics GmbH

Target Recruit Count: 27

Registration Number: NCT00761280

Locations: 🇦🇷
FLENI, Ciudad Autónoma de Buenos Aires, Argentina
🇺🇸
NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

and more 64 locations

Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Lomustine

First Posted Date: 2008-01-11

Last Posted Date: 2014-04-02

Lead Sponsor: University Hospital, Bordeaux

Target Recruit Count: 459

Registration Number: NCT00590837

Locations: 🇫🇷
Service Hématologie, Hôpital Augustin Morvan, Brest, France
🇫🇷
Services maladies du sang, cancérologie, Hôpital Sud, CHU Amiens, Amiens, France
🇫🇷
Service des maladies du sang, Centre Hospitalier Universitaire d'Angers, Angers, France

and more 29 locations

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

Phase 1

Completed

Conditions: Melanoma
Brain Neoplasms

Interventions: Drug: Lomustine
Drug: Temozolomide
Drug: Thalidomide

First Posted Date: 2007-09-11

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00527657

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

Phase 2

Completed

Conditions: Glioblastoma Multiforme
Anaplastic Glioma of Brain
Brain Cancer

Interventions: Drug: Capecitabine
Drug: Celecoxib (Celebrex)
Drug: Temozolomide
Drug: Lomustine
Drug: 6-Thioguanine

First Posted Date: 2007-07-20

Last Posted Date: 2012-01-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT00504660

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Phase 1

Completed

Conditions: Recurrent Glioblastoma
Brain Tumor

Interventions: Drug: Cediranib
Drug: Lomustine

First Posted Date: 2007-07-18

Last Posted Date: 2009-11-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT00503204

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Not Applicable

Conditions: Lymphoma

First Posted Date: 2006-04-24

Last Posted Date: 2015-09-25

Lead Sponsor: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma

Target Recruit Count: 96

Registration Number: NCT00317408

Locations: 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪
Krankenhaus Muenchen Schwabing, Munich, Germany

and more 91 locations

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Not Applicable

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-03-17

Last Posted Date: 2014-01-28

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 567

Registration Number: NCT00303810

Locations: 🇩🇪
University Medical Center Hamburg - Eppendorf, Hamburg, Germany

Enzastaurin Versus Lomustine in Glioblastoma

Phase 3

Completed

Conditions: Glioblastoma

Interventions: Drug: enzastaurin
Drug: lomustine

First Posted Date: 2006-02-24

Last Posted Date: 2019-09-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 397

Registration Number: NCT00295815

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom

Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2013-05-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 42

Registration Number: NCT00293280

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy